Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy

Natsuko Iga, Atsushi Otsuka, Masahiro Hirata, Tatsuki R. Kataoka, Hiroyuki Irie, Chisa Nakashima, Shigeto Matsushita, Hiroshi Uchi, Yuki Yamamoto, Takeru Funakoshi, Yasuhiro Fujisawa, Koji Yoshino, Taku Fujimura, Hiroo Hata, Yoshihiro Ishida, Kenji Kabashima

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Immune checkpoint inhibitors have improved the prognosis of advanced melanoma. Although anti–programmed death ligand-1 (PD-L1) is a well-studied biomarker for response to anti–programmed death-1 PD-1 therapy in melanoma, its clinical relevance remains unclear. It has been established that the high expression of indoleamine 2,3-dioxygenase (IDO) is correlated to a response to anti–CTLA-4 treatment in melanoma. However, it is still unknown whether the IDO expression is associated with response to anti–PD-1 therapy in advanced melanoma. In addition, acral and mucosal melanomas, which comprise a great proportion of all melanomas in Asians, are genetically different subtypes from cutaneous melanomas; however, they have not been independently analyzed due to their low frequency in Western countries. To evaluate the association of IDO and PD-L1 expression with response to anti–PD-1 antibody in acral and mucosal melanoma patients, we analyzed 32 Japanese patients with acral and mucosal melanomas treated with anti–PD-1 antibody from the perspective of IDO and PD-L1 expression levels by immunohistochemistry (IHC). Multivariate Cox regression models showed that the low expression of IDO in tumors was associated with poor progression-free survival (HR = 0.33, 95% CI = 0.13-0.81, P = 0.016), whereas PD-L1 expression on tumors was not associated with progression-free survival. Significantly lower expression of IDO in tumors was found in non–responders compared to responders. Assessment of the IDO expression could be useful for the identification of suitable candidates for anti–PD-1 therapy among acral and mucosal melanomas patients. Further validation study is needed to estimate the clinical utility of our findings.

Original languageEnglish
Pages (from-to)3434-3441
Number of pages8
JournalCancer science
Volume110
Issue number11
DOIs
Publication statusPublished - 2019 Nov 1

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Immunotherapy
Melanoma
Extremities
Disease-Free Survival
Neoplasms
Antibodies
Validation Studies
Therapeutics
Proportional Hazards Models
Biomarkers
Immunohistochemistry

Keywords

  • 3-dioxygenase
  • checkpoint inhibitor
  • IDO
  • indoleamine 2
  • melanoma
  • PD-1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Iga, N., Otsuka, A., Hirata, M., Kataoka, T. R., Irie, H., Nakashima, C., ... Kabashima, K. (2019). Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. Cancer science, 110(11), 3434-3441. https://doi.org/10.1111/cas.14195

Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. / Iga, Natsuko; Otsuka, Atsushi; Hirata, Masahiro; Kataoka, Tatsuki R.; Irie, Hiroyuki; Nakashima, Chisa; Matsushita, Shigeto; Uchi, Hiroshi; Yamamoto, Yuki; Funakoshi, Takeru; Fujisawa, Yasuhiro; Yoshino, Koji; Fujimura, Taku; Hata, Hiroo; Ishida, Yoshihiro; Kabashima, Kenji.

In: Cancer science, Vol. 110, No. 11, 01.11.2019, p. 3434-3441.

Research output: Contribution to journalArticle

Iga, N, Otsuka, A, Hirata, M, Kataoka, TR, Irie, H, Nakashima, C, Matsushita, S, Uchi, H, Yamamoto, Y, Funakoshi, T, Fujisawa, Y, Yoshino, K, Fujimura, T, Hata, H, Ishida, Y & Kabashima, K 2019, 'Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy', Cancer science, vol. 110, no. 11, pp. 3434-3441. https://doi.org/10.1111/cas.14195
Iga, Natsuko ; Otsuka, Atsushi ; Hirata, Masahiro ; Kataoka, Tatsuki R. ; Irie, Hiroyuki ; Nakashima, Chisa ; Matsushita, Shigeto ; Uchi, Hiroshi ; Yamamoto, Yuki ; Funakoshi, Takeru ; Fujisawa, Yasuhiro ; Yoshino, Koji ; Fujimura, Taku ; Hata, Hiroo ; Ishida, Yoshihiro ; Kabashima, Kenji. / Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. In: Cancer science. 2019 ; Vol. 110, No. 11. pp. 3434-3441.
@article{afc9bf20564c4643ba942f7cf22518aa,
title = "Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy",
abstract = "Immune checkpoint inhibitors have improved the prognosis of advanced melanoma. Although anti–programmed death ligand-1 (PD-L1) is a well-studied biomarker for response to anti–programmed death-1 PD-1 therapy in melanoma, its clinical relevance remains unclear. It has been established that the high expression of indoleamine 2,3-dioxygenase (IDO) is correlated to a response to anti–CTLA-4 treatment in melanoma. However, it is still unknown whether the IDO expression is associated with response to anti–PD-1 therapy in advanced melanoma. In addition, acral and mucosal melanomas, which comprise a great proportion of all melanomas in Asians, are genetically different subtypes from cutaneous melanomas; however, they have not been independently analyzed due to their low frequency in Western countries. To evaluate the association of IDO and PD-L1 expression with response to anti–PD-1 antibody in acral and mucosal melanoma patients, we analyzed 32 Japanese patients with acral and mucosal melanomas treated with anti–PD-1 antibody from the perspective of IDO and PD-L1 expression levels by immunohistochemistry (IHC). Multivariate Cox regression models showed that the low expression of IDO in tumors was associated with poor progression-free survival (HR = 0.33, 95{\%} CI = 0.13-0.81, P = 0.016), whereas PD-L1 expression on tumors was not associated with progression-free survival. Significantly lower expression of IDO in tumors was found in non–responders compared to responders. Assessment of the IDO expression could be useful for the identification of suitable candidates for anti–PD-1 therapy among acral and mucosal melanomas patients. Further validation study is needed to estimate the clinical utility of our findings.",
keywords = "3-dioxygenase, checkpoint inhibitor, IDO, indoleamine 2, melanoma, PD-1",
author = "Natsuko Iga and Atsushi Otsuka and Masahiro Hirata and Kataoka, {Tatsuki R.} and Hiroyuki Irie and Chisa Nakashima and Shigeto Matsushita and Hiroshi Uchi and Yuki Yamamoto and Takeru Funakoshi and Yasuhiro Fujisawa and Koji Yoshino and Taku Fujimura and Hiroo Hata and Yoshihiro Ishida and Kenji Kabashima",
year = "2019",
month = "11",
day = "1",
doi = "10.1111/cas.14195",
language = "English",
volume = "110",
pages = "3434--3441",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy

AU - Iga, Natsuko

AU - Otsuka, Atsushi

AU - Hirata, Masahiro

AU - Kataoka, Tatsuki R.

AU - Irie, Hiroyuki

AU - Nakashima, Chisa

AU - Matsushita, Shigeto

AU - Uchi, Hiroshi

AU - Yamamoto, Yuki

AU - Funakoshi, Takeru

AU - Fujisawa, Yasuhiro

AU - Yoshino, Koji

AU - Fujimura, Taku

AU - Hata, Hiroo

AU - Ishida, Yoshihiro

AU - Kabashima, Kenji

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Immune checkpoint inhibitors have improved the prognosis of advanced melanoma. Although anti–programmed death ligand-1 (PD-L1) is a well-studied biomarker for response to anti–programmed death-1 PD-1 therapy in melanoma, its clinical relevance remains unclear. It has been established that the high expression of indoleamine 2,3-dioxygenase (IDO) is correlated to a response to anti–CTLA-4 treatment in melanoma. However, it is still unknown whether the IDO expression is associated with response to anti–PD-1 therapy in advanced melanoma. In addition, acral and mucosal melanomas, which comprise a great proportion of all melanomas in Asians, are genetically different subtypes from cutaneous melanomas; however, they have not been independently analyzed due to their low frequency in Western countries. To evaluate the association of IDO and PD-L1 expression with response to anti–PD-1 antibody in acral and mucosal melanoma patients, we analyzed 32 Japanese patients with acral and mucosal melanomas treated with anti–PD-1 antibody from the perspective of IDO and PD-L1 expression levels by immunohistochemistry (IHC). Multivariate Cox regression models showed that the low expression of IDO in tumors was associated with poor progression-free survival (HR = 0.33, 95% CI = 0.13-0.81, P = 0.016), whereas PD-L1 expression on tumors was not associated with progression-free survival. Significantly lower expression of IDO in tumors was found in non–responders compared to responders. Assessment of the IDO expression could be useful for the identification of suitable candidates for anti–PD-1 therapy among acral and mucosal melanomas patients. Further validation study is needed to estimate the clinical utility of our findings.

AB - Immune checkpoint inhibitors have improved the prognosis of advanced melanoma. Although anti–programmed death ligand-1 (PD-L1) is a well-studied biomarker for response to anti–programmed death-1 PD-1 therapy in melanoma, its clinical relevance remains unclear. It has been established that the high expression of indoleamine 2,3-dioxygenase (IDO) is correlated to a response to anti–CTLA-4 treatment in melanoma. However, it is still unknown whether the IDO expression is associated with response to anti–PD-1 therapy in advanced melanoma. In addition, acral and mucosal melanomas, which comprise a great proportion of all melanomas in Asians, are genetically different subtypes from cutaneous melanomas; however, they have not been independently analyzed due to their low frequency in Western countries. To evaluate the association of IDO and PD-L1 expression with response to anti–PD-1 antibody in acral and mucosal melanoma patients, we analyzed 32 Japanese patients with acral and mucosal melanomas treated with anti–PD-1 antibody from the perspective of IDO and PD-L1 expression levels by immunohistochemistry (IHC). Multivariate Cox regression models showed that the low expression of IDO in tumors was associated with poor progression-free survival (HR = 0.33, 95% CI = 0.13-0.81, P = 0.016), whereas PD-L1 expression on tumors was not associated with progression-free survival. Significantly lower expression of IDO in tumors was found in non–responders compared to responders. Assessment of the IDO expression could be useful for the identification of suitable candidates for anti–PD-1 therapy among acral and mucosal melanomas patients. Further validation study is needed to estimate the clinical utility of our findings.

KW - 3-dioxygenase

KW - checkpoint inhibitor

KW - IDO

KW - indoleamine 2

KW - melanoma

KW - PD-1

UR - http://www.scopus.com/inward/record.url?scp=85073980544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073980544&partnerID=8YFLogxK

U2 - 10.1111/cas.14195

DO - 10.1111/cas.14195

M3 - Article

C2 - 31509303

AN - SCOPUS:85073980544

VL - 110

SP - 3434

EP - 3441

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -